首页> 美国卫生研究院文献>Journal of Cardiovascular and Thoracic Research >Transcatheter heart valve in valve implantation with Edwards SAPIEN bioprosthetic valve for different degenerated bioprosthetic valve positions (First Iranian ViV report with mid-term follow up)
【2h】

Transcatheter heart valve in valve implantation with Edwards SAPIEN bioprosthetic valve for different degenerated bioprosthetic valve positions (First Iranian ViV report with mid-term follow up)

机译:经导管心脏瓣膜植入Edwards SAPIEN生物人工瓣膜可用于不同的退化生物人工瓣膜位置(伊朗的第一份ViV报告中期随访)

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Introduction: After early successful experience with transcatheter aortic valve replacement (TAVR), concept of transcatheter implantation of a new valve within a failing bioprosthetic valve emerged. Valve-in-valve (ViV) implantation seems to be a simpler option for high risk surgical patients. >Methods: We performed five ViV procedures in different valve positions. We included patients with failing bioprosthetic valves with high surgical risk due to concomitant comorbidities. We performed 2 transapical ViV procedures for failing mitral bioprosthetic valves, 1 transfemoral procedure for failing pulmonary valve and 2 transfemoral ViV implantation for failing tricuspid bioprosthetic valves. >Results: The procedures were successfully completed in all 5 cases with initial excellent fluoroscopic and echocardiographic verification. There was no valve embolization or paravalvular leakage in any of the cases. Transcatheter valve function was appropriate with echocardiography. Post procedural clinical adverse events like pleural effusion and transient ischemic attack were managed successfully. In midterm follow up all cases remained in appropriate functional class except from the transcatheter pulmonary valve which became moderately stenotic and regurgitant. >Conclusion: As the first Iranian all-comers case series with midterm follow up for ViV implantation, we had no mortality. Interestingly none of our patients had neurologic sequelae after the procedure. Midterm follow up for our patients was acceptable with good functional class and appropriate echocardiographic findings. Due to high surgical risk of the redo procedure after failing of a bioprosthetic valve especially in elderly patients with comorbidities, ViV implantation would be a good alternative to surgery for this high risk group.
机译:>简介:在导管主动脉瓣置换术(TAVR)的早期成功经验之后,出现了在出现故障的生物人工瓣膜中经导管植入新瓣膜的概念。对于高风险手术患者,瓣膜植入(ViV)似乎是一个更简单的选择。 >方法:我们在不同的阀门位置执行了五次ViV程序。我们纳入了因合并症而具有高手术风险的生物人工瓣膜衰竭的患者。我们对二尖瓣生物瓣膜瓣膜进行了2次经心尖ViV手术,对肺动脉瓣膜瓣膜瓣膜进行了1次经股骨手术,对三尖瓣生物瓣膜瓣膜进行了2次经股骨ViV植入。 >结果:通过最初的出色的荧光检查和超声心动图检查,所有5例患者均成功完成了手术。在任何情况下都没有瓣膜栓塞或瓣周漏。经导管瓣膜功能适合超声心动图检查。成功处理了诸如胸腔积液和短暂性脑缺血发作等程序后临床不良事件。在中期随访中,除经导管肺动脉瓣变中度狭窄和反流外,所有病例均处于适当的功能类别。 >结论:作为第一个对ViV植入进行中期随访的伊朗全民病例系列,我们没有死亡。有趣的是,我们的患者在手术后都没有神经系统后遗症。我们患者的中期随访是可以接受的,具有良好的功能分类和适当的超声心动图检查结果。由于生物瓣膜失效后重做手术的手术风险较高,尤其是对于合并症的老年患者,对于这一高风险人群,ViV植入将是手术的理想选择。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号